Evidence map›Paper›PMID 33179096›Full record

ArticleMolecular medicine reports2021

Long non‑coding RNA TTN‑AS1 regulates the proliferation, invasion and migration of triple‑negative breast cancer by targeting miR‑211‑5p.

Erhu Sun, Xiaofeng Liu, Cheng Lu, Kangsheng Liu

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Erhu SunDepartment of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R. China.
Xiaofeng LiuDepartment of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R. China.
Cheng LuDepartment of Breast, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R. China.
Kangsheng LiuDepartment of Clinical Laboratory, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu 210000, P.R. China.
Nanjing Maternity and Child Health Care Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence has demonstrated that long non‑coding RNAs (lncRNAs) serve important roles in numerous malignancies, including triple‑negative breast cancer (TNBC). The lncRNA titin‑antisense RNA1 (TTN‑AS1) has previously been reported to promote tumorigenesis in various types of cancer. The present study aimed to investigate the potential role of TTN‑AS1 in breast cancer and the associated underlying mechanisms. Following prediction by Starbase and confirmation by dual‑luciferase reporter assay, TINCR was demonstrated to be a target gene for microRNA (miR)‑211‑5p. The expression levels of TTN‑AS1 and miR‑211‑5p, which was predicted to be targeted by TTN‑AS1, in TNBC tissues and in the breast cancer cell lines MDA‑MB‑453 and MDA‑MB‑231 were measured using reverse transcription‑quantitative PCR. Following TTN‑AS1‑knockdown, cell proliferation was measured using a Cell Counting Kit‑8 assay and colony formation assay, whereas cell invasion and migration were measured using Transwell and wound healing assays, respectively. Luciferase reporter assay was performed to verify the potential interaction between TTN‑AS1 and miR‑211‑5p. In addition, rescue assays were conducted to investigate the effects of TTN‑AS1 and miR‑211‑5p on TNBC development. The results demonstrated that TTN‑AS1 expression was significantly upregulated, whereas that of miR‑211‑5p was found to be downregulated in TNBC tissues and cell lines compared with the matched adjacent normal tissues and normal breast epithelial cell line MCF‑10A, respectively. Furthermore, TTN‑AS1‑knockdown inhibited the proliferation and invasive and migratory abilities of MDA‑MB‑453 and MDA‑MB‑231 cells, which was reversed following co‑transfection with the miR‑211‑5p inhibitor. The results from luciferase reporter assay confirmed that miR‑211‑5p was a direct target of TTN‑AS1, suggesting that TTN‑AS1 may bind directly to miR‑211‑5p to negatively regulate its expression. In conclusion, the findings from the present study demonstrated that TTN‑AS1 regulated the proliferation and invasive and migratory abilities of TNBC by targeting miR‑211‑5p. This study may provide some insights into the regulatory mechanism of TNBC and help the development of novel therapeutic interventions for TNBC.

Indexed as

Up-RegulationAdultAgedCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMicroRNAsMiddle AgedNeoplasm InvasivenessRNA, Long NoncodingTriple Negative Breast NeoplasmsMicroRNAsMIRN211 microRNA, humanRNA, Long Noncodingbreast cancerinvasionmicroRNA‑211‑5pmigrationproliferationtitin‑antisense RNA1

Identifiers

PMID33179096
PMCPMC7684865
OpenAlexW3101249348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.